The production of retatrutide, a novel dual agonist targeting both GLP-1 and GIP receptors, represents a complex multi-step synthetic process. Early routes focused on amino acid chain portion coupling, utilizing solid-phase creation methodologies to build the long protein sequence. Subsequent Glucogon research has explored different approaches, in